Curium's Investigational New Drug Application Accepted by Center for Drug Evaluation in China

-- Curium's Investigational New Drug (IND) application for 177Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer (mCRPC), has been accepted by the ...
Yahoo Finance

Curium to become major player in the supply on non carrier added Lu-177

LONDON, Jan. 25, 2022 (GLOBE NEWSWIRE) -- Today Curium has announced a technology license agreement granting access to ECZACIBAŞI MONROL NÜKLEER ÜRÜNLER SANAYİ VE TİCARET A.Ş non carrier added ...
Yahoo Finance

CapVest recapitalizes Curium to accelerate its growth strategy, marking the largest transaction in nuclear medicine globally

The recapitalization will accelerate Curium’s strategy to launch innovative, life-changing diagnostic and therapeutic solutions for cancer patients around the world BOSTON, Nov. 20, 2025 (GLOBE ...
Medindia

Curium Strengthens Its PET Manufacturing Capacity and Expands European Footprint with the Acquisition of Nucleis

PARIS, April 10, 2025 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today that it has completed the acquisition of Nucleis, a specialist in GMP manufacturing and ...
The National Law Review

Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

Positions Curium as leading manufacturer of Lu-177 isotope Brings innovative R&D expertise and pipeline to Curium Enhances Curium’s SPECT & PET geographical coverage and supply chain PARIS, March 28, ...
Kauppalehti

Curium’s Investigational New Drug Application Accepted by Center for Drug Evaluation in China

Curium’s Investigational New Drug (IND) application for 177 Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer (mCRPC), has been accepted by the Centre ...
MarketWatch

CapVest recapitalizes Curium to accelerate its growth strategy, marking the largest transaction in nuclear medicine globally

The MarketWatch News Department was not involved in the creation of this content. -- Curium and CapVest have announced the recapitalization of Curium via a new Continuation Vehicle -- The transaction ...
Morningstar

Curium Completes the Acquisition of Monrol as Part of its Plan to Significantly Expand Lutetium-177 Capacity and PET Footprint

PARIS, March 28, 2025 (GLOBE NEWSWIRE) -- Curium Pharma (“Curium”), a world leader in nuclear medicine, is pleased to announce the completion of its acquisition of Eczacıbaşı-Monrol Nuclear Products ...
Finanznachrichten

Curium's Investigational New Drug Application Accepted by Center for Drug Evaluation in China

Curium's Investigational New Drug (IND) application for 177 Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer (mCRPC), has been accepted by the Centre ...